Skip to main content

Day: December 30, 2024

Sydbank share buyback programme: transactions in week 52

        Company Announcement No 62/2024Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk30 December 2024  Dear Sirs Sydbank share buyback programme: transactions in week 52On 28 February 2024 Sydbank announced a share buyback programme of DKK 1,200m. The share buyback programme commenced on 4 March 2024 and will be completed by 31 January 2025. The purpose of the share buyback programme is to reduce the share capital of Sydbank and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules. The following transactions have been made under the share...

Continue reading

Share buyback programme – week 52

Nasdaq CopenhagenEuronext DublinLondon Stock ExchangeDanish Financial Supervisory AuthorityOther stakeholders Date        30 December 2024 Share buyback programme – week 52 The share buyback programme runs in the period 1 February 2024 up to and including 27 January 2025, see company announcement of 31 January 2024. Part I of the programme, for DKK 750 million, was completed on 27 June 2024, see company announcement of 28 June 2024. Part II of the programme, for DKK 775 million and a maximum of 1,550,000 shares, is for execution in the period 28 June 2024 – 27 January 2025. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” rules. The following transactions have...

Continue reading

Himax to Introduce Expanded WiseEye PalmVein Suite at CES 2025 Featuring Groundbreaking Bimodal Palm Vein and Face Authentication Technologies for Multimodal Authentication

Redefining Biometric Security for Smart Door Locks with Ultralow Power WiseEye PalmVein and Face Authentication Technologies for Rapid, Contactless, and Adaptive Identity Verification TAINAN, Taiwan, Dec. 30, 2024 (GLOBE NEWSWIRE) — Himax Technologies, Inc. (“Himax” or “Company”) (Nasdaq: HIMX), an industry leader in fabless display driver ICs and other semiconductors, today announced the Company will introduce its expanded WiseEyeTM PalmVein suite at CES 2025, featuring groundbreaking bimodal palm vein and face authentication technologies. This game-changing, contactless, ultralow power bimodal biometric authentication is designed to enhance both security and user friendliness in smart door locks. By leveraging multiple personal biometric traits for authentication, the newly introduced solution delivers unparalleled security,...

Continue reading

Endeavour Announces Transaction in Own Shares

         ENDEAVOUR ANNOUNCES TRANSACTION IN OWN SHARES London, 30 December 2024 – Endeavour Mining plc (LSE:EDV, TSX:EDV) (“the Company”) announces it has purchased the following number of its ordinary shares of USD 0.01 each from Stifel Nicolaus Europe Limited. Aggregated informationDates of purchase: 27 December 2024Aggregate number of ordinary shares of USD 0.01 each purchased: 23,452Lowest price paid per share (GBp):                 1,415.00Highest price paid per share (GBp):         1,445.59Volume weighted average price paid per share (GBp):         1,416.40Following the cancellation of the repurchased shares, the Company will have no ordinary shares in treasury and 244,036,385 ordinary shares in issue. Therefore the total voting rights in the Company will be 244,036,385. This figure for the total number of voting...

Continue reading

Vastned Belgium and Vastned Retail expect to complete their reverse cross-border legal merger on 1 January 2025

In line with required notification periods for listing purposes, Vastned Belgium (Vastned Belgium NV, Euronext Brussels: VASTB, a public regulated real estate company (GVV/SIR)) announces today that it expects that the reverse cross-border legal merger, in which Vastned Retail (Vastned Retail N.V., Euronext Amsterdam: VASTN) would merge with and into Vastned Belgium (Merger), will enter into force on 1 January 2025 at 00.00 am CET (i.e., start of the day) and Vastned Belgium will be renamed to “Vastned”. Full press release:AttachmentVastned Belgium and Vastned Retail expect to complete their reverse cross-border legal merger on 1 January 2025

Continue reading

Garden Stage Limited – Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Hong Kong, Dec. 30, 2024 (GLOBE NEWSWIRE) — Garden Stage Limited (NASDAQ: GSIW) (“GSIW” or the “Company”), today announced that it received a delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on December 24, 2024 indicating that the Company is not currently in compliance with the minimum bid price requirement set forth in Nasdaq’s Listing Rules for continued listing on the Nasdaq Capital Market, as the closing bid price for the Company’s ordinary shares listed on the Nasdaq Capital Market was below $1.00 per share for 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price...

Continue reading

Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA

Ad hoc announcement pursuant to Art. 53 LRThe Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec (OAV101 IT) OAV101 IT is the first investigational gene therapy to provide clinical benefit in treatment-naïve patients with SMA aged two and older with a positive risk benefit profile Novartis plans to share results with regulatory agencies in 2025 with the aim to make OAV101 IT available to help patients with SMA in needBasel, [December 30, 2024] – Novartis today announced positive topline results from the Phase III STEER study. This pivotal study assessed the efficacy and safety of investigational intrathecal onasemnogene abeparvovec (OAV101 IT) in treatment-naïve patients with spinal muscular atrophy (SMA) Type 2,...

Continue reading

WISeKey’s Subsidiary SEALCOIN 2025 Roadmap: Leading Machine-to-Machine Transactions Through Blockchain and Space Innovation

WISeKey’s Subsidiary SEALCOIN 2025 Roadmap: Leading Machine-to-Machine Transactions Through Blockchain and Space Innovation Zug, Switzerland — December 30, 2024 – WISeKey International Holding Ltd (“WISeKey” or the “Company”) (NASDAQ: WKEY; SIX: WIHN), a global leader in cybersecurity, AI, blockchain, and IoT technologies, that its subsidiary, SEALCOIN AG, ends 2024 as a leader in secure, decentralized IoT ecosystems. Utilizing its blockchain-based TIOT token, SEALCOIN empowers IoT devices to autonomously exchange data, energy, and services, transforming real-time interactions with unmatched trust and efficiency. In January 2025, SEALCOIN will achieve a major milestone in cooperation with WISeSat AG, another WISeKey subsidiary which focuses on space technology for secure satellite communication, specifically for IoT applications,...

Continue reading

Anoto announces outcome of rights issue

Anoto Group AB (the “Company” or “Anoto“) hereby announces the outcome of the Company’s rights issue of approximately SEK 50 million (the “Rights Issue”) for which the subscription period ended on 19 December 2024. The Rights Issue has been subscribed to approximately 37.5 percent with and without the support of subscription rights. Underwriting commitments of 259,308,520 shares, corresponding to approximately 62.5 percent of the Rights Issue, will thus be utilized. The Rights Issue provides the Company with proceeds of approximately SEK 50 million before transaction costs and before set-off of loans. Final outcomeIn the Rights Issue, 154,891,590 shares were subscribed for with subscription rights, corresponding to approximately 37.3 percent of the Rights Issue. In addition, 623,720 shares were subscribed for without...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.